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bjectives We performed this study to investigate with optical coherence tomography (OCT) the
ascular response after sirolimus-eluting stent (SES) implantation between patients with and those
ithout diabetes mellitus (DM).
ackground The difference in vascular response after SES implantation between patients with and
hose without DM has not been fully evaluated with OCT.
ethods Optical coherence tomography was performed to examine 74 nonrestenotic SES im-
lanted in 63 patients (32 with DM and 31 without DM) at 9 months after SES implantation. For
truts showing neointimal coverage, the neointimal thickness on the luminal side of each strut sec-
ion was measured, and neointimal characteristics were classiﬁed into high, low, and layered signal
attern.
esults Baseline patient characteristics and lesion and procedural characteristics data were similar
etween the 2 groups. In total, 11,422 struts were analyzed. High signal neointima was observed in
0.2  13.9%, low signal neointima in 7.3  10.0%, and layered neointima in 2.7  5.8%/stents.
here was higher incidence of low signal neointima (10.5  10.3% vs. 4.5  5.6%, p  0.003), neo-
ntimal thickness was larger (median: 106.8 m, interquartile range: 79.3 to 130.4 m vs. median:
3.5 m, interquartile range: 62.3 to 89.3 m; p  0.0001), and neointimal coverage of stent struts
as higher (92.1  6.2% vs. 87.2  11.9%; p  0.03) in DM patients.
onclusions High signal neointimal pattern was predominantly observed, and low or layered signal
attern was observed in some cases. In DM patients, low signal neointima was observed with high
requency. Neointimal coverage and neointimal thickness was also higher in DM patients as com-
ared with non-DM patients. (J Am Coll Cardiol Intv 2010;3:1074–9) © 2010 by the American
ollege of Cardiology Foundation
rom the Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan. The authors have reported that they have no
elationships to disclose. Drs. Tanaka and Rathore have contributed equally to this paper.anuscript received March 24, 2010; revised manuscript received June 17, 2010, accepted August 5, 2010.
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1075he introduction of the drug-eluting stent (DES) has
esulted in suppressing neointimal hyperplasia and thereby
educing restenosis rates as compared with bare-metal stent
BMS) (1,2). However, the issue of late stent thrombosis
as emerged as a safety concern (3) with the use of DES.
iabetes mellitus (DM) has been shown to be a strong
ndependent predictor of restenosis (4,5) and late stent
hrombosis (6,7) after sirolimus-eluting stent (SES) implan-
ation. Therefore, it has been postulated that vascular
ealing and response in patients with DM after SES
mplantation might be different from patients without DM.
ptical coherence tomography (OCT) has been recently
sed for daily clinical practice. Because resolution of OCT
s 10 (10 to 20 m) higher than intravascular ultrasound
IVUS), the stent strut coverage with neointima after
mplantation could be better visualized and quantified by
CT. To date, the difference in vascular healing and
ascular response after SES implantation in patients with
nd those without DM has not been reported. The objective
f this study is to evaluate the differences and patterns of
ascular healing and vascular response at 9 months after
ES implantation in patients with (DM group) and those
ithout DM (non-DM group) as assessed by OCT.
ethods
atient population. We evaluated 74 nonrestenotic SES
Cypher, Cordis, Miami Lakes, Florida) implanted in 63
atients (32 DM group, 31 non-DM group), who agreed to
ndergo follow-up coronary angiography and OCT study.
he OCT analysis and coronary angiography was per-
ormed at 9 months after SES implantation. All patients
eceived dual antiplatelet therapy with aspirin 100 mg/day
nd ticlopidine 200 mg/day or clopidogrel 75 mg/day before
nd after SES implantation. The DM group was defined as
atients treated with oral diabetes agent or insulin at the
ime of percutaneous coronary intervention.
We excluded patients with ST-segment elevated myocar-
ial infarction, contraindication to dual antiplatelet therapy,
estenotic lesions after balloon angioplasty, left ventricular
jection fraction 30%, chronic renal dysfunction as indi-
ated by serum creatinine more than 1.5 mg/dl, left main
oronary artery lesions, ostial lesions and severe tortuous
esion, failure to obtain clear image by IVUS or OCT, or
esions inappropriate for IVUS or OCT examination. The
tudy was approved by our institutional review board, and
ritten informed consent was obtained from all study
atients before catheterization.
uantitative coronary angiographic analysis. All baseline,
rocedural, and follow-up angiography was performed im-
ediately after administration of 200 g of intracoronary
itroglycerin, and the treated lesion was evaluated with 2 or
ore angiographic projections. Quantitative coronary an-
iography (QCA) was performed by 2 experienced angiog- caphers with the Cardiovascular Measurement System
CMS-MEDIS, Medical Imaging Systems, Leiden, the
etherlands). Lesion length, reference diameter, minimal
umen diameter (MLD), and percentage diameter stenosis
ere measured with the view showing the smallest lumen
iameter at diastolic frames. The QCA analysis was per-
ormed at baseline, after procedure, and 9-month follow-up.
cute gain was defined as the difference between baseline
nd post-procedural MLD, and late loss was defined as the
ifference between post-procedural and follow-up MLD.
CT image acquisition. The OCT image acquisition was
erformed with a commercially available system for intra-
oronary imaging (LightLab Imaging, Inc., Westford, Mas-
achusetts). The ImageWire (LightLab Imaging, Inc.) was
ositioned distal to the stented segment with over-the-wire
ype occlusion balloon catheter (Helios, LightLab Imag-
ng Inc.). To clear blood from the imaging site, the
cclusion balloon was inflated to 0.5 to 0.7 atm with a
ustomized inflation device, and
actated Ringer’s solution was
nfused into the coronary artery
rom the distal tip of the occlu-
ion balloon at the rate of 0.5 to
.9 ml/s. Motorized pullback
CT imaging was performed at
rate of 1.0 mm/s. All images
f the stents were acquired at
5 frames/s and were digitally
tored for offline analysis.
CT image analysis. Offline anal-
sis was performed with the pro-
rietary LightLab software (Light-
ab Imaging). Cross-sectional
CT images were analyzed at
-mm intervals by 2 independent
bservers, who were blinded to
linical and procedural characteristics. The stented segment
as defined as the region between the first and the last
rame with circumferentially visible struts on the OCT
mage. The stent strut apposition to the vessel wall and
eointimal coverage were assessed for each stent strut. Fully
overed stent strut was defined as complete coverage of the
tent strut on the luminal side by visible neointima. This
eans that neointimal thickness has to be at least 10 m to
e detected by the OCT. The malapposition of a strut was
efined as a distance of 170 m between the middle of
tent strut reflection and the vessel wall (8). Strut coverage
atio and mean neointimal thickness were examined on a
er-stent basis. Binary strut coverage (%) was calculated as:
number of strut sections covered/total number of strut
ections examined)  100 (9). For struts showing neointi-
al coverage, the neointimal thickness on the luminal side
f each strut section was measured, and the neointimal
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
DM  diabetes mellitus
IVUS  intravascular
ultrasound
MLD  minimal lumen
diameter
OCT  optical coherence
tomography
QCA  quantitative coronary
angiography
SES  sirolimus-eluting
stent(s)haracteristics were classified into high signal pattern: neo-
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1076ntima is of high density and line could not be drawn
etween neointimal layer and intima, because of high signal
ntensity throughout; low signal pattern: neointima is of low
ensity, and we can clearly draw the line between neointimal
ayer and intima; and layered signal pattern: neointima is of
ixed density, and deeper layers are low density, and the
uminal side is high density (Fig. 1).
tatistical analysis. Statistical analysis was performed with
tatView version 5 (SAS Institute, Inc. Cary, North Caro-
ina). Data were expressed as mean  SD or as median
25th, 75th percentile) for continuous variables and as
requencies for categorical variables. The chi-square test or
isher exact test was used for comparing frequencies of
ccurrence. Continuous variables between different catego-
ies were compared by either Mann-Whitney U test or
npaired t test. Stent-wise comparisons were made by a
ingle experienced observer without correction. A p value
0.05 was considered to be statistically significant.
esults
aseline clinical, lesion, and procedural characteristics. The
aseline patient demographic, lesion, and procedural char-
cteristics for both groups are shown in Tables 1 and 2.
aseline patient, lesion, and procedural characteristics were
imilar in the 2 groups. Follow-up angiography and OCT
nalysis was performed at 9.2  1.8 months in the DM
roup and 9.1  1.5 months in the non-DM group (p 
.8). In addition, there was no significant difference in the
ual antiplatelet therapy compliance between the 2 groups
aspirin and ticlopidine or clopidogrel; 96.9% in the DM
roup, 93.5% in the non-DM group; p  0.54) during
ollow up. All OCT images at follow-up were acquired
uccessfully without any complications.
CA data analysis. The QCA data are shown in Table 3.
aseline angiographic variables were similar for both
roups. Furthermore, there was no significant difference in
Figure 1. Neointimal Classification at 9-Month Follow-Up After Sirolimus-El
Neointimal characteristics were classiﬁed into high signal pattern, low signal phe post-procedural MLD, percentage diameter stenosis,nd acute gain between the 2 groups. At 9-month follow-
p, MLD was larger, and percentage diameter stenosis was
ower in the non-DM group, as compared with the DM
roup (2.70  0.39 mm vs. 2.21  0.55 mm, p  0.01, and
1.0  9.2% vs. 17.1  12.8%, p  0.03, respectively).
urthermore, late loss was larger in the DM group than in
he non-DM group (0.32  0.39 mm vs. 0.02  0.34 mm,
 0.01).
CT analysis. The OCT analysis was performed at 9-month
ollow-up to examine the implanted 74 SES in 63 patients
32 with diabetes, and 31 without diabetes) (Table 4). There
ere no incidences of ventricular fibrillation, vessel injury,
r visible thrombus formation during the OCT procedure.
n total 11,242 strut sections were analyzed. Stent strut
Stent Implantation
, and layered signal pattern, as indicated by white arrows.
Table 1. Baseline Patient Characteristics
Variables
DM Group
(n  32)
Non-DM Group
(n  31) p Value
Age, yrs 65.1 10.4 68.5 11.5 0.22
Male sex 27 (84.4) 23 (74.2) 0.32
Hypertension 25 (78.1) 25 (80.6) 0.80
Hyperlipidemia 20 (62.5) 24 (77.4) 0.20
Current smoking 12 (37.5) 10 (32.3) 0.66
Renal dysfunction (Cr 1.2) 1 (3.1) 1 (3.2) 0.98
Prior myocardial infarction 9 (28.1) 7 (22.6) 0.61
Prior PCI 14 (43.8) 15 (48.4) 0.71
Prior CABG 1 (3.1) 1 (3.2) 0.98
Multi-vessel involvement 27 (84.4) 26 (83.9) 0.96
Unstable angina pectoris 5 (15.6) 5 (16.1) 0.96
Chronic stable angina 27 (84.4) 26 (83.9) 0.96
LVEF, % 52.4 9.3 53.8 8.4 0.55
Statin 21 (65.6) 20 (64.5) 0.93
ACEI, ARB 20 (62.5) 18 (58.1) 0.72
Dual antiplatelet therapy 31 (96.9) 29 (93.5) 0.54
Values are given as mean SD or n (%).
ACEI  angiotensin converting enzyme inhibitor; ARB  angiotensin receptor blocker;
CABG  coronary artery bypass surgery; Cr  creatinine; DM  diabetes mellitus; LVEF  leftutingventricular ejection fraction; PCI percutaneous coronary intervention.
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1077overage and neointimal thickness at 9 months were signif-
cantly higher in the DM group compared with the
on-DM group (92.1  6.2% vs. 87.2  11.9%; p  0.03)
Fig. 2), (median: 106.8 m, interquartile range: 79.3 to
30.4 m vs. median: 83.5 m, interquartile range: 62.3 to
9.3 m; p  0.0001), respectively (Fig. 3).
In terms of distribution of different patterns of neointimal
haracteristics, high signal pattern of neointima was domi-
antly seen in this analysis: high signal pattern (90.2 
3.9%), low signal pattern (7.3 10.0%), and layered signal
attern (2.7  5.8%) (Fig. 4).
The different pattern of neointimal characteristics was
lso assessed between DM and non-DM groups (Fig. 5).
he frequency of high signal pattern was observed sig-
ificantly higher in the non-DM group (86.2  14.3% vs.
4.0  7.6%; p  0.004), whereas low signal pattern was
bserved significantly more frequently in the DM group
10.5  10.3% vs. 4.5  5.6%; p  0.003). The frequency
Table 3. Quantitative Angiographic Data Before, After, and Follow-Up Period
Variables
DM Group
(n  32)
Non-DM Group
(n  31) p Value
Lesion length, mm 21.8 11.1 18.2 8.0 0.14
Reference diameter, mm 2.57 0.60 2.78 0.39 0.08
Minimal lumen diameter, mm
Before procedure 0.90 0.34 1.06 0.36 0.06
After procedure 2.63 0.56 2.83 0.38 0.18
Follow-up 2.21 0.55 2.70 0.39 0.01
% diameter stenosis
Before procedure 64.6 12.0 62.0 11.8 0.37
After procedure 9.80 8.30 12.4 11.3 0.29
Follow-up 17.1 12.8 11.0 9.2 0.03
Acute gain, mm 1.63 0.47 1.69 0.41 0.93
Late loss, mm 0.32 0.39 0.02 0.34 0.01
Values are given as mean SD.
Table 2. Lesion and Procedural Characteristics
Variables
DM Group
(n  32)
Non-DM Group
(n  31) p Value
Vessel treated
LAD 13 (40.6) 14 (45.2)
LCx 10 (31.3) 9 (29.0) 0.72
RCA 9 (28.1) 8 (25.8)
AHA/ACC typeB2/C lesion 27 (84.4) 25 (80.6) 0.70
Stent diameter, mm 2.89 0.37 3.03 0.32 0.11
Stent length, mm 22.7 5.8 20.8 5.1 0.66
Multiple overlapping stents 6 (18.8) 5 (16.1) 0.78
Maximum inﬂation pressure, atm 17.8 3.7 18.3 4.1 0.59
Values are given as n (%) or mean SD.
AHA/ACC  American Heart Association/American College of Cardiology; DM  diabetes
mellitus; LAD left anterior descendingartery; LCx left circumflex; RCA right coronary artery.DM diabetes mellitus.f layered signal pattern was observed similarly between the
groups (3.2  5.6% vs. 1.4  3.4%).
iscussion
he main findings of our study are: 1) there was a
ignificantly higher number of stent struts covered with
eointima, and there was higher neointimal thickness in
atients with diabetes mellitus as compared with non-DM
atients after SES implantation at 9 months; 2) there was
igher incidence of low signal pattern neointima seen in
atients with diabetes mellitus.
Some other studies (10) have shown that 90% of the stent
truts were covered by neointima after 6 months of SES
mplantation, as observed by OCT. These results are similar
o our study. Previous studies using IVUS analysis in BMS
ave shown that in-stent neointimal hyperplasia was larger
n patients with DM as compared with non-DM patients. It
as been suggested that DM itself causes exaggerated
ntimal hyperplasia and is the major risk factor for higher
n-stent restenosis rate (11).
Treatment with DES significantly suppresses neointimal
roliferation in patients with DM in comparison with BMS
Figure 2. Comparison of Neointimal Coverage Rate Between DM Group
and Non-DM Group
Table 4. OCT Analysis at Follow-Up Period
Variables
DM Group
(n  32)
Non-DM Group
(n  31) p Value
No. of stents, n 38 36 —
No. of stent struts counted, n 5,921 5,321 —
Covered struts 92.1 6.2 87.2 11.9 0.03
Neointimal thickness, m 106.8 (79.3–130.4) 83.5 (62.3–89.3) 0.0001
High signal neointima 86.2 14.3 94.0 7.6 0.004
Low signal neointima 10.5 10.3 4.5 5.6 0.003
Layered signal neointima 3.2 5.6 1.4 3.4 0.1
Values are given as %, mean SD, or median (interquartile range).
DM diabetes mellitus; OCT optical coherence tomography.DM  diabetes mellitus.
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107812,13). Moussa et al. (12) and Jiménez-Quevedo et al. (13)
ave commented that, despite the significant reductions in
ate loss and restenosis in diabetic patients receiving the
irolimus-eluting stent, the absolute late loss and restenosis
emain higher than that observed in non-DM patients. We
ave also shown higher late loss in the DM group, and our
CT analysis showed more frequent stent strut coverage,
hicker neointima, and higher neointimal hyperplasia in
atients with DM as compared with non-DM after SES
mplantation.
These results are supported by the fact that the effective-
ess of Rapamycin for inhibiting migration of smooth
uscle cells is less subject to hyperglycemic conditions as
ompared with normoglycemia (14). Diabetes is known to
e associated with hormonal and vascular abnormalities that
romote smooth muscle cell proliferation after vascular
njury, including injury after coronary interventions (15).
ncreased smooth muscle proliferation in diabetic patients
Figure 3. Box Plots Showing Comparison of Neointimal Thickness
Between DM and Non-DM Groups
Values for neointimal thickness (m) are presented as median with an
interquartile range and minimum and maximum values at the extreme.
DM  diabetes mellitus.
Figure 4. Distribution of Neointimal Characteristics for Stent StrutsgShowing Neointimal Coverageight result from mitogens (such as platelet-derived growth
actor and insulin-like growth factor) that stimulate cell
rowth and deleterious vascular effects of endothelial dys-
unction and excessive extracellular matrix production
16,17).
The incidence of stent thrombosis has been related to the
igher incidence of exposed stent struts and poor endothe-
ialization in the previous study (13). However, they have
ot observed different composition of neointima as a cause
f stent thrombosis. Ideally, the higher amount of neoin-
ima and endothelialization of the stent struts should be
rotective of stent thrombosis in diabetic patients. On the
ontrary, diabetes mellitus has been identified as an inde-
endent predictor of stent thrombosis after SES implanta-
ion (6,7). The exact underlying mechanism is unknown,
nd it has been postulated that diabetic patients have
ultivessel coronary artery disease and higher risk profile,
redisposing them for stent thrombosis.
The characteristics and the quality of neointima forma-
ion could potentially contribute to this higher rate of stent
hrombosis in diabetic patients. Interestingly, we have
bserved a significantly higher frequency of neointima with
ow signal pattern in patients with diabetes mellitus as
ompared with patient without diabetes mellitus. Neoin-
ima pattern after BMS implantation has mainly shown
igh signal pattern (18), whereas the low-signal pattern seen
n the present study was different from the usual pattern of
eointima. Despite excessive intimal proliferation and fa-
orable stent strut coverage, stent thrombosis rates tend to
e higher in patients with DM in the clinical setting. This
ontradictory phenomenon can be explained by “the differ-
nce in characteristics and quality of neointimal formation.”
he pathological assessment by Joner et al. (19) has sug-
Figure 5. Difference of Neointimal Characteristics Between DM and
Non-DM Groups
High signal pattern was signiﬁcantly higher in non-DM group (mean  SD,
86.2  14.3% vs. 94.0  7.6%; p  0.004); low signal pattern was signiﬁ-
cantly more frequent in DM group (mean  SD, 10.5  10.3% vs. 4.5 
5.6%; p  0.003). DM  diabetes mellitus.ested that the significant, incomplete endothelialization
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1079nd persistent fibrin deposition were observed after DES
sirolimus-, paclitaxel-eluting stent) implantation as com-
ared with BMS implantation.
Neointima observed as low signal pattern by OCT in the
resent study could be composed of immature neointima, extra
ellular matrix, organized thrombi, and proteoglycan caused by
elayed re-endothelialization, as seen in pathological studies
16,17). These changes could play a role in the pathogenesis of
hrombus formation. Moreover, patients with DM as com-
ared with non-DM patients have exaggerated vascular endo-
helial damage after stent implantation. As a consequence,
eointima that is observed as low signal pattern could be
aused by delayed re-endothelialization. However, there is no
istopathological data to support this hypothesis.
Larger studies involving serial assessment of the neointima
y OCT are needed to further elucidate this process. More-
ver, comparison and correlation between OCT characteristics
nd histopathological specimens obtained during atherectomy
ould help in understanding the composition of neointima.
linical association between type of neointimal formation by
CT and stent thrombosis needs to be confirmed.
tudy limitations. First, this study is a retrospective, observa-
ional study of prospectively collected data. Second, the sample
ize was relatively small. Third, there is a lack of clinical
ollow-up data. A large randomized multicenter clinical study
s warranted to more accurately evaluate the vascular response
fter DES implantation in patients with diabetes mellitus.
onclusions
his is the first study analyzing the OCT characteristics of
eointima after SES implantation in patients with diabetes.
e have observed that efficacy of suppressing neointimal
roliferation is attenuated in patients with DM as compared
ith patients without DM. Furthermore, a low-signal
attern of neointima was observed with higher frequency in
M patients, suggesting different vascular response and
eointima proliferation in DM patients as compared with
on-DM patients.
eprint requests and correspondence:Dr. Mitsuyasu Terashima,
oyohashi Heart Center, 21-1 Gobudori, Oyama-cho, Toyohashi
41-8530, Japan. E-mail: terashima@heart-center.or.jp.
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